Side-effects of fat jabs are transforming the dating scene – and ‘reshaping' our sex lives
For the 1.5 million Brits already on them, many are likely to be shedding the pounds, and fast.
1
Weight loss jabs are shaking up people's sex and dating lives
Credit: Getty
While new studies suggest they may make people healthier, by slashing the risk of heart disease and curing booze addiction.
But that's not all - these so-called 'fat jabs' could be changing the way we flirt, date and have sex too.
According to a survey by the Kinsey Institute, at Indiana University in the US, nearly half of people using GLP-1 drugs said the meds had changed their sex lives - for better, or worse.
Some users reported feeling a serious boost in desire, feeling sexier naked, and noticing better performance in the bedroom.
But it wasn't all good news, others said their libido took a hit, or that they felt less comfortable with their bodies, even as the weight dropped off.
"There's a very nuanced story to tell here," Dr Justin Lehmiller, one of the study's authors said.
"How these drugs impact your sex life will depend on a variety of factors, including dosage, speed of weight loss and changes to fitness habits.'
The research conducted with DatingNews.com polled 2,000 single adults in the US, aged 18 to 91.
Of those, 8 per cent, just 160 people, said they'd used weight-loss jabs like Ozempic or Wegovy.
Among those users, nearly 60 per cent said the medication had affected their dating lives.
Feeling Full Naturally: Top 5 Foods That Act Like Weight Loss Jabs
They reported a range of benefits, from getting more matches on dating apps to feeling confident enough to ask people out.
Nearly one in six users said they had bought new clothes to show off their bodies, while others noticed exes reaching out, sparked by their transformations.
Around 13 per cent felt more confident posting photos online, and 12 per cent said they were going on more dates.
Sexual desire increased for 18 per cent of users, but 16 per cent experienced the opposite effect.
Similarly, 16 per cent felt more comfortable naked, while 14 per cent felt less so.
Improvements in sexual function were reported by 16 per cent, but 12 per cent said their sexual performance had worsened.
Men see the biggest difference
Men in particular reported more pronounced shifts, both positive and negative.
They were twice as likely as women to say their libido had increased, they were happier with their bodies, and that their sexual function improved.
Yet they were also more likely to report decreased libido and sexual difficulties.
Despite the boost in confidence many felt, 60 per cent of men admitted to worrying about being judged or shamed for taking these medications, compared to 35 per cent of women.
Dr Amanda Gesselman, another study author, added: 'GLP-1 use is rising among single adults and it's starting to influence more than just how people look and feel about themselves.
"These shifts have the potential to reshape how people build intimacy in today's dating landscape.
"For example, as users report reduced appetites and lower interest in alcohol, the classic dinner-and-drinks date may give way to new ways of connecting.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
2 hours ago
- Scottish Sun
The exact number of daily steps to slash your risk of dying young by almost 50% – and it's loads less than you think
Find out what happened to Sun Health's Alice Fuller when she challenged herself to walk 10,000 each day for an entire year STEP UP The exact number of daily steps to slash your risk of dying young by almost 50% – and it's loads less than you think Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FOR decades, 10,000 steps a day has been drilled into us as the ultimate daily goal to keep fit and healthy. But new research shows you could move far less and still boost your health, slash the risk of disease, and even live longer. Sign up for Scottish Sun newsletter Sign up 1 A brisk daily walk of 7,000 steps may protect your brain and heart Credit: Getty A study led by scientists from the University of Sydney in Australia found that walking just 7,000 steps each day can reduce your risk of dementia, heart disease and dying early. Even modest step counts of 4,000 steps a day can reap benefits over very low levels of activity, experts found. But they added that "10,000 steps per day will still be better than 7,000 steps" - with the higher step count leading to more health benefits. This isn't the first study to suggest you don't need to hit 10,000 steps a day to claim the rewards. Read more on living longer LIVE LONG & PROSPER Nine daily tasks to help you live longer & they take a few minutes Separate research, published by London scientists last year, found that walking just 5,000 steps three days a week can increase life expectancy by three years. Meanwhile, a Polish study from 2023 found getting your step count up to 2,337 each day was enough to slash your risk of heart disease. The new study, published in The Lancet Public Health, saw researchers examine data from dozens of studies from around the world, including in the UK, on tens of thousands of adults. They found that walking just 7,000 steps a day was linked to a 25 per cent lower risk of heart disease. It was also associated with a 14 per cent reduced risk of type 2 diabetes, a 38 per cent lower risk of dementia, and a 22 per cent reduced risk of depression. The researchers also found that when people walked 7,000 daily steps, compared to walking 2,000 steps, they were 47 per cent less likely to die during the follow-up periods of the studies analysed. Get fit at 50: Workouts for beginners and those short on time And while the number of steps walked did not sway whether or not a person got cancer, people who walked more steps were 37 per cent less likely to die from cancer. "Although 10,000 steps per day can still be a viable target for those who are more active, 7,000 steps per day is associated with clinically meaningful improvements in health outcomes and might be a more realistic and achievable target for some," the authors wrote in the study. "Even modest daily step counts were associated with health benefits," they added. "7,000 steps per day was associated with sizeable risk reductions across most outcomes, compared with the reference of 2,000 steps per day." 'More is always better' Commenting on the study, Dr Daniel Bailey, Reader - Sedentary Behaviour and Health, Brunel University of London, said: "The finding that doing 5000-7000 steps per day is an important addition to the literature which helps to debunk the myth that 10,000 steps per day should be the target for optimal health. "This study suggested that 5,000-7,000 steps per day can significantly reduce the risk of many health outcomes, but that does not mean you cannot get benefits if you don't meet this target. "The study also found that health risks were reduced with each 1000 extra steps per day, up to a maximum of 12,000 steps per day. So just adding more steps from your starting point can have important benefits for health." Dr Andrew Scott, senior Lecturer in clinical exercise physiology at the University of Portsmouth, added: "In most cases the 10,000 steps per day will still be better than 7,000 steps, just by decreasing margins of health benefit return. "More important than the exact number of steps, it demonstrates that overall, more is always better and people should not focus too much on the numbers, particularly on days where activity is limited. "The steps per day is useful when people's exercise is weight-bearing, however, cycling, swimming and rowing are not well-represented by the steps per day model."
Scottish Sun
2 hours ago
- Scottish Sun
Shop-bought health tests not fit for purpose, warn experts – as they present ‘significant risk' for wrong diagnosis
The self-test market is booming in Britain TESTING TIMES Shop-bought health tests not fit for purpose, warn experts – as they present 'significant risk' for wrong diagnosis Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) SHOP-BOUGHT medical tests are unreliable and need tougher regulation, say scientists. The kits are readily available from supermarkets for checking health factors like high cholesterol, vitamin deficiencies, fertility and prostate problems. Sign up for Scottish Sun newsletter Sign up 1 Self-testing became normal during the Covid pandemic Credit: Getty But experts warn 'evidence for their benefit is lacking'. A study by the University of Birmingham found many cannot back up claims about their accuracy. Testing found many have confusing or unreadable instructions, and customers often do not know what to do with their results. Scientists said they should go through more stringent quality checks and be regulated like medical products. Professor Jon Deeks said: 'Current regulations are not adequately protecting consumers. 'For matters of our health, it is important that the evidence upon which health decisions are made is available and can be scrutinised.' Kits cost as little as £1.89 There is a booming market for the tests, which mostly work like Covid lateral flow tests, and the UK industry is set to be worth half a billion pounds by 2030. Researchers bought 30 of the kits from shops around Birmingham, costing between £1.89 and £39.99, and evaluated them. They found at least 18 had 'high risk' problems that might lead to a wrong result or decision. Eleven had equipment quality issues, 10 did not have a proper sampling process and 15 had issues with the instructions or advice on what to do with the results. British Heart Foundation video explains what exactly is meant by the risk of high cholesterol Those with problems included tests for menopause hormones, kidney function, vitamin D and thyroid function. In one example, Prof Deeks said the self-tests for prostate-specific antigen (PSA) levels, a marker of prostate health, were fixed at a certain concentration level. However, 'if you're age 70 you need to have your PSA done at a very different level to when you're 20', he said. False results could put strain on the NHS Dr Clare Davenport said: 'A good test should be clear about who and when to use it. 'It should be easy to use and easy to interpret. 'We expect it to be accurate and we expect it to be evidence-based if it's going to be sold to the general public, with clear advice of what to do with next steps. 'Unfortunately, what we found is that actually many tests gave unclear or missing guidance. 'On one side, if you get a false positive result that might lead to unnecessary extra testing, unnecessary treatments or just anxiety to patients. 'And on the other side, you may have a false negative and you get this false reassurance, which can lead to missed or delayed diagnosis and delayed treatment with obviously worse outcomes for patients. 'All of this can have an impact on health care demand. 'The wrong test or result can then lead to unnecessary or additional appointments, investigations and treatments and a higher burden on the NHS.' Dr Bernie Croal, president of the Royal College of Pathologists, said: 'There are significant risks to patients when poor quality tests are carried out inappropriately.' However, the team said that in the future, home tests could have great potential for patient care. The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medical products, said it would look at the findings. It issued its own warning about the kits in June and said they must not be taken as real medical advice. The MHRA said: 'Self-tests can provide helpful insights, but they're not a substitute for medical advice or a diagnosis. 'If you're unsure about a result, or have symptoms you're worried about, speak to a GP, pharmacist or other healthcare professional before making any decisions.' The research was published in the British Medical Journal.
Daily Mail
4 hours ago
- Daily Mail
Common virus that affects 124million Americans may contribute to debilitating multiple sclerosis
About one in two adults is infected with a virus that can cause cold sores, fever and blisters in the mouth. But now, researchers at the University of Illinois Chicago (UIC) suggest that oral herpes, caused by herpes simplex virus-1 (HSV-1), could also raise the risk of suffering from the life-altering condition multiple sclerosis. In a new study, scientists gene-edited mice not to produce a protein called optineurin, which plays a role in defending the body against herpes infections, and then infected the mice with the virus. The infection led to the rapid degradation of the myelin sheath, a protective coating on nerve fibers. This caused mice to suffer MS-like symptoms, such as muscle weakness, loss of movement and the ability to coordinate muscles. This mirrors the process observed in individuals with multiple sclerosis, where the myelin sheath also degrades because the immune system misfires and starts to attack the area. The scientists say their findings could indicate a link between HSV-1, which is different from the HSV-2 virus that causes genital herpes, and MS. Dr Deepak Shukla, a professor of molecular virology at UIC and the study's lead, said: 'Our findings enhance our understanding of how viruses develop and offer potential avenues for mitigating viral-induced [nerve cell] damage. 'If you are infected, then your immune system is constantly locked in battle with the virus. And if for any reason you become immunocompromised, the virus can escape and damage your brain.' Oral herpes is an extremely common condition that infects about 47 percent of adults, according to the CDC, or 124million people. The virus is spread via sexual contact, such as kissing and oral sex, and is incurable, normally lying dormant and triggering occasional flare-ups of sores on and around the mouth and lips. In cells, it is controlled by the protein optineurin, which stops an infection from spreading and protects against any potential myelin sheath damage. Scientists have previously established that one of the biggest risk factors for MS is an infection with the Epstein-Barr virus (EBV), a virus that has infected 95 percent of adults and which is estimated to raise the risk of MS by 30 percent. And other herpes viruses, like the ones that cause chickenpox, shingles, and human herpes virus 6, have also been linked to the onset and worsening of MS, which affects 1 million Americans. And MS is a debilitating, incurable autoimmune condition that affects the brain and spinal cord and leaves people with mobility issues, memory loss and fatigue. In earlier studies, Dr Shukla's team found that HSV-1 triggered a strong immune response in the brains of mice, causing memory problems, poor coordination, and anxiety. They also discovered that the protein optineurin helps fight the virus by slowing its growth and spread. In the latest study, researchers infected mice that could not produce the protein with the oral herpes virus in their eyes. As seen in earlier cell tests, mice without optineurin had higher infection rates after four days. The researchers also found that a protein called MLKL, or Mixed Lineage Kinase Domain-Like protein, which is made by the body during cell death, boosted HSV-1 infections in the absence of optineurin. Researchers said the protein facilitated the transportation of the virus into a cell's nucleus, speeding an infection, and optineurin controlled HSV-1 infection by triggering the deterioration of MLKL. Imaging studies revealed extensive clumping, or aggregation, of MLKL in the brains of optineurin-lacking mice, but not in control mice, in response to HSV-1 infection. Also, these clumps appeared to trigger the death of myelin-producing oligodendrocytes, or cells that create armor, or the myelin sheath, around neurons. Without the sheath, the nervous system was left vulnerable to damage. The resulting damage disrupts the communication between the brain and the rest of the body, leading to the various symptoms associated with MS, such as weakness in the legs, fatigue, coordination problems, cognitive changes, and pain. Identifying this protein offers a new target for multiple sclerosis therapies. Already, Shukla's lab has demonstrated that necrosulfonamide, which inhibits optineurin, can preserve nerve function in animal models. Studies like these provide hope for the future of MS, and bring about the potential to enable earlier intervention or a possible cure.
